# A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

> **NCT07232004** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 87 (estimated)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ABBV-547
- **DRUG:** ABBV-547 Placebo

## Key facts

- **NCT ID:** NCT07232004
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232004, "A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07232004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*